Detection of Influenza and Other Respiratory Viruses in Air Sampled From a University Campus: A Longitudinal Study.


Journal

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213

Informations de publication

Date de publication:
14 02 2020
Historique:
received: 16 01 2019
accepted: 04 04 2019
pubmed: 10 4 2019
medline: 7 1 2021
entrez: 10 4 2019
Statut: ppublish

Résumé

Respiratory virus-laden particles are commonly detected in the exhaled breath of symptomatic patients or in air sampled from healthcare settings. However, the temporal relationship of detecting virus-laden particles at nonhealthcare locations vs surveillance data obtained by conventional means has not been fully assessed. From October 2016 to June 2018, air was sampled weekly from a university campus in Hong Kong. Viral genomes were detected and quantified by real-time reverse-transcription polymerase chain reaction. Logistic regression models were fitted to examine the adjusted odds ratios (aORs) of ecological and environmental factors associated with the detection of virus-laden airborne particles. Influenza A (16.9% [117/694]) and influenza B (4.5% [31/694]) viruses were detected at higher frequencies in air than rhinovirus (2.2% [6/270]), respiratory syncytial virus (0.4% [1/270]), or human coronaviruses (0% [0/270]). Multivariate analyses showed that increased crowdedness (aOR, 2.3 [95% confidence interval {CI}, 1.5-3.8]; P < .001) and higher indoor temperature (aOR, 1.2 [95% CI, 1.1-1.3]; P < .001) were associated with detection of influenza airborne particles, but absolute humidity was not (aOR, 0.9 [95% CI, .7-1.1]; P = .213). Higher copies of influenza viral genome were detected from airborne particles >4 μm in spring and <1 μm in autumn. Influenza A(H3N2) and influenza B viruses that caused epidemics during the study period were detected in air prior to observing increased influenza activities in the community. Air sampling as a surveillance tool for monitoring influenza activity at public locations may provide early detection signals on influenza viruses that circulate in the community.

Sections du résumé

BACKGROUND
Respiratory virus-laden particles are commonly detected in the exhaled breath of symptomatic patients or in air sampled from healthcare settings. However, the temporal relationship of detecting virus-laden particles at nonhealthcare locations vs surveillance data obtained by conventional means has not been fully assessed.
METHODS
From October 2016 to June 2018, air was sampled weekly from a university campus in Hong Kong. Viral genomes were detected and quantified by real-time reverse-transcription polymerase chain reaction. Logistic regression models were fitted to examine the adjusted odds ratios (aORs) of ecological and environmental factors associated with the detection of virus-laden airborne particles.
RESULTS
Influenza A (16.9% [117/694]) and influenza B (4.5% [31/694]) viruses were detected at higher frequencies in air than rhinovirus (2.2% [6/270]), respiratory syncytial virus (0.4% [1/270]), or human coronaviruses (0% [0/270]). Multivariate analyses showed that increased crowdedness (aOR, 2.3 [95% confidence interval {CI}, 1.5-3.8]; P < .001) and higher indoor temperature (aOR, 1.2 [95% CI, 1.1-1.3]; P < .001) were associated with detection of influenza airborne particles, but absolute humidity was not (aOR, 0.9 [95% CI, .7-1.1]; P = .213). Higher copies of influenza viral genome were detected from airborne particles >4 μm in spring and <1 μm in autumn. Influenza A(H3N2) and influenza B viruses that caused epidemics during the study period were detected in air prior to observing increased influenza activities in the community.
CONCLUSIONS
Air sampling as a surveillance tool for monitoring influenza activity at public locations may provide early detection signals on influenza viruses that circulate in the community.

Identifiants

pubmed: 30963180
pii: 5432328
doi: 10.1093/cid/ciz296
pmc: PMC7108140
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

850-858

Subventions

Organisme : NIAID NIH HHS
ID : HHSN272201400006C
Pays : United States

Informations de copyright

© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Références

Clin Infect Dis. 2019 Jul 2;69(2):197-203
pubmed: 30452608
J R Soc Interface. 2009 Dec 6;6 Suppl 6:S783-90
pubmed: 19773292
Indoor Air. 2017 May;27(3):564-575
pubmed: 27687789
J Infect Dis. 2018 Mar 13;217(7):1074-1077
pubmed: 29300926
PLoS Pathog. 2013 Mar;9(3):e1003205
pubmed: 23505369
mSphere. 2018 Jul 11;3(4):
pubmed: 29997120
Clin Infect Dis. 2016 Feb 15;62(4):431-437
pubmed: 26518469
Influenza Other Respir Viruses. 2016 Sep;10(5):404-13
pubmed: 26991074
Euro Surveill. 2016 Sep 1;21(35):
pubmed: 27608369
Lancet Infect Dis. 2017 Nov;17(11):1133-1161
pubmed: 28843578
J Clin Microbiol. 2013 Dec;51(12):3960-7
pubmed: 24048533
PLoS One. 2016 Feb 05;11(2):e0148669
pubmed: 26849130
Curr Opin Virol. 2018 Feb;28:142-151
pubmed: 29452994
J Infect Dis. 2004 Feb 15;189(4):652-7
pubmed: 14767819
Emerg Infect Dis. 2006 Nov;12(11):1657-62
pubmed: 17283614
PLoS Biol. 2010 Feb 23;8(2):e1000316
pubmed: 20186267
Clin Infect Dis. 2010 Mar 1;50(5):693-8
pubmed: 20100093
Clin Infect Dis. 2009 Feb 15;48(4):438-40
pubmed: 19133798
Lancet Infect Dis. 2007 Apr;7(4):257-65
pubmed: 17376383
J Infect Dis. 2013 Apr;207(7):1037-46
pubmed: 23372182
Lancet. 2018 Mar 31;391(10127):1285-1300
pubmed: 29248255
Lancet. 2017 Sep 2;390(10098):946-958
pubmed: 28689664
J R Soc Interface. 2011 Aug 7;8(61):1176-84
pubmed: 21300628
Proc Natl Acad Sci U S A. 2018 Jan 30;115(5):1081-1086
pubmed: 29348203
Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3243-8
pubmed: 19204283
J Infect Dis. 2012 Dec 15;206(12):1862-71
pubmed: 23045622
PLoS One. 2016 Mar 04;11(3):e0151004
pubmed: 26942410
J Clin Microbiol. 2011 Apr;49(4):1653-6
pubmed: 21270233
mSphere. 2017 Oct 11;2(5):
pubmed: 29034325
Lancet Infect Dis. 2002 Feb;2(2):111-4
pubmed: 11901642
J Clin Microbiol. 2013 Apr;51(4):1124-9
pubmed: 23345299

Auteurs

Chenyi Xie (C)

School of Public Health, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong Special Administrative Region, China.

Eric H Y Lau (EHY)

School of Public Health, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong Special Administrative Region, China.

Tomoyo Yoshida (T)

School of Public Health, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong Special Administrative Region, China.

Han Yu (H)

Department of Mechanical Engineering, University of Hong Kong, Hong Kong Special Administrative Region, China.

Xin Wang (X)

School of Public Health, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong Special Administrative Region, China.

Huitao Wu (H)

School of Public Health, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong Special Administrative Region, China.

Jianjian Wei (J)

Department of Mechanical Engineering, University of Hong Kong, Hong Kong Special Administrative Region, China.

Ben Cowling (B)

School of Public Health, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong Special Administrative Region, China.

Malik Peiris (M)

School of Public Health, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong Special Administrative Region, China.

Yuguo Li (Y)

Department of Mechanical Engineering, University of Hong Kong, Hong Kong Special Administrative Region, China.

Hui-Ling Yen (HL)

School of Public Health, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong Special Administrative Region, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH